Omda (OMDA) Aktievy
Omda AS tillhandahåller mjukvarulösningar för hälso- och sjukvårdssektorn i Norge, Sverige, Danmark, Finland och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 5/6 |
| Framtida tillväxt | 5/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 1/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
OMDA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Omda AS Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | NOK 36.80 |
| 52 veckors högsta | NOK 53.80 |
| 52 veckors lägsta | NOK 33.00 |
| Beta | 0.42 |
| 1 månads förändring | 0.55% |
| 3 månaders förändring | -10.02% |
| 1 års förändring | -27.84% |
| 3 års förändring | -10.46% |
| 5 års förändring | -59.11% |
| Förändring sedan börsintroduktionen | -55.66% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Jun 02
OMDA: Q4 Execution And 2026 Guidance Conservatism Will Shape Future Upside Potential
Narrative Update on Omda The updated analyst price target for Omda shifts from a fair value of NOK57.00 to NOK50.00 as analysts factor in a higher discount rate, more cautious revenue growth assumptions, improved profit margin expectations, and a lower future P/E multiple. Analyst Commentary Recent Street research on Omda highlights a mix of optimism about growth and execution, paired with more cautious valuation assumptions and price target resets.Analysartikel • May 23
Omda AS (OB:OMDA) Just Reported, And Analysts Assigned A kr50.00 Price Target
Last week, you might have seen that Omda AS ( OB:OMDA ) released its quarterly result to the market. The early response...Uppdatering av berättelse • May 10
OMDA: Q4 Execution And 2026 Guidance Conservatism Will Drive Future Upside Potential
Analysts now place Omda's fair value at NOK 57.0, with the updated price target shaped by refreshed discount rate assumptions and recent mixed but generally constructive research commentary on guidance, growth drivers and valuation in the sector. Analyst Commentary Recent research on Omda reflects an active debate on how to balance strong reported execution with more cautious valuation and guidance assumptions.Recent updates
Uppdatering av berättelse • Jun 02
OMDA: Q4 Execution And 2026 Guidance Conservatism Will Shape Future Upside Potential
Narrative Update on Omda The updated analyst price target for Omda shifts from a fair value of NOK57.00 to NOK50.00 as analysts factor in a higher discount rate, more cautious revenue growth assumptions, improved profit margin expectations, and a lower future P/E multiple. Analyst Commentary Recent Street research on Omda highlights a mix of optimism about growth and execution, paired with more cautious valuation assumptions and price target resets.Analysartikel • May 23
Omda AS (OB:OMDA) Just Reported, And Analysts Assigned A kr50.00 Price Target
Last week, you might have seen that Omda AS ( OB:OMDA ) released its quarterly result to the market. The early response...Uppdatering av berättelse • May 10
OMDA: Q4 Execution And 2026 Guidance Conservatism Will Drive Future Upside Potential
Analysts now place Omda's fair value at NOK 57.0, with the updated price target shaped by refreshed discount rate assumptions and recent mixed but generally constructive research commentary on guidance, growth drivers and valuation in the sector. Analyst Commentary Recent research on Omda reflects an active debate on how to balance strong reported execution with more cautious valuation and guidance assumptions.Uppdatering av berättelse • Apr 20
OMDA: Q4 Execution And 2026 Guidance Conservatism Will Support Upside Potential
Analysts have adjusted their Omda price target to NOK57.0, with only marginal tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions after recent research highlighted both reduced targets across several firms and continued confidence in Omda's growth runway and program momentum. Analyst Commentary Street research around Omda presents a mix of recalibrated price targets and continued confidence in the company’s ability to execute on its program pipeline.Uppdatering av berättelse • Apr 06
OMDA: Q4 Outperformance And 2026 Guidance Conservatism Are Expected To Drive Upside
The updated analyst price target for Omda now reflects a more cautious tone seen across recent NOK-based targets, as analysts factor in refreshed models following Q4 results, revised guidance and ongoing debate around how conservative the medium-term outlook might be. Analyst Commentary Street research on Omda clusters around lowered price targets in the near term, but most firms are maintaining positive or neutral ratings, pointing to a mix of execution momentum and valuation questions.Uppdatering av berättelse • Mar 23
OMDA: Multi Condition Momentum And 2026 Guidance Are Expected To Drive Upside
Analysts have trimmed the Omda fair value estimate from NOK 59 to NOK 57, reflecting updated price targets and modeling that factors in revised profit margin expectations, alongside supportive views on revenue growth and the broader program momentum flagged in recent research notes. Analyst Commentary Recent Street research on Omda points to a reset in expectations around valuation, while still highlighting execution on growth initiatives and Q4 performance.Uppdatering av berättelse • Mar 08
OMDA: Multi Condition Momentum And 2026 Guidance Are Expected To Unlock Upside
Analysts have nudged our Omda price target slightly lower to NOK 59.0, reflecting modestly higher discount rate and P/E assumptions while still citing solid Q4 execution, program momentum and a generally supportive tone across recent research updates. Analyst Commentary Recent research paints a mixed but generally constructive picture around Omda, with most firms trimming price targets while still pointing to solid execution and program traction after Q4.Uppdatering av berättelse • Feb 22
OMDA: Cardiometabolic Partnerships And Reduced Multiple Are Expected To Unlock Upside
Analysts have trimmed their Omda price targets by about NOK 3, reflecting slightly higher discount rate assumptions and a lower future P/E multiple, as they balance growth expectations with recent stock performance and client concentration risks. Analyst Commentary Recent Street research on Omda highlights a mix of optimism around the core business and caution around how that story translates into valuation and execution risk.Uppdatering av berättelse • Feb 07
OMDA: Cardiometabolic Program Expansion And AI Platform Investment Will Drive Future Upside
Analysts have trimmed their average price targets on Omda by a few dollars, reflecting a slightly higher discount rate and a modestly higher assumed future P/E, while still pointing to a mix of growth opportunities in cardiometabolic programs and client concentration risks. Analyst Commentary Recent research on Omda reflects a mix of optimism around long term growth potential and caution around execution and concentration risks.Uppdatering av berättelse • Jan 24
OMDA: GLP-1 Companion Expansion And AI Investment Will Drive Future Upside
Analysts have trimmed their blended price target for Omda by a few dollars to align with recent cuts and initiations around the $17 to $32 range, citing a combination of strong GLP-1 related momentum, partnership tailwinds, revenue growth potential, and concerns about client concentration and ownership complexity. Analyst Commentary Recent research on Omda reflects a mix of optimism around growth drivers and caution around concentration risks and ownership structure, which together help frame how analysts think about valuation and execution risk.Uppdatering av berättelse • Jan 10
OMDA: Cardiometabolic Platform Expansion And AI Execution Will Support Future Upside Potential
Analysts have slightly adjusted their outlook on Omda, with a modest change in the implied fair value and Street price targets. This reflects updated views on discount rates, long term growth drivers, and mixed recent research that includes lower targets from Goldman Sachs and Wells Fargo, alongside more constructive targets from BMO Capital and Morgan Stanley.Uppdatering av berättelse • Dec 22
OMDA: Expanded GLP-1 Programs And AI Offerings Will Drive Future Margin Upside
Analysts have raised their price target on Omda to $59.00, supported by expectations for sustained revenue growth above 20%, expanding margins, and accelerating adoption of its enhanced GLP-1 programs and AI driven offerings. Analyst Commentary Recent Street research reflects a predominantly constructive stance on Omda, with bullish analysts highlighting a combination of strong execution, favorable unit economics, and a long runway for growth as key drivers of upside to the newly raised price target.Uppdatering av berättelse • Dec 08
OMDA: GLP 1 Program Expansion Will Drive Future Margin Upside
Analysts have raised their price target on Omda to $59.00 per share from a previously implied lower level, citing expectations for sustained 20% plus revenue growth, expanding margins, and accelerating GLP 1 related momentum as key drivers of upside. Analyst Commentary Recent Street commentary highlights a constructive backdrop for Omda, with bullish analysts pointing to a long runway for growth supported by a large, under-penetrated market, strong execution, and accelerating GLP 1 related initiatives.Uppdatering av berättelse • Nov 24
OMDA: Expanding Market And AI Integration Will Drive Continued Growth Momentum
Analysts have significantly raised Omda's fair value estimate from $35 to $59. They cite strong revenue growth, improved profit margins, an expanding addressable market, and increased momentum in new product rollouts and profitability.Analysartikel • Oct 10
Returns On Capital Are Showing Encouraging Signs At Omda (OB:OMDA)
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...Uppdatering av berättelse • Aug 23
M&A And Competition Will Shape Risk And Opportunity In Healthcare
Despite Omada’s stronger-than-expected growth in members and revenue, robust gross margin gains, and improving clinical partnerships, analysts have lowered the price target from NOK44.00 to NOK35.00 due to a more cautious broader outlook. Analyst Commentary Bullish analysts highlight Omada’s member and revenue growth significantly surpassing expectations, with first-quarter figures beating estimates by 6.7% and 11.5%, respectively.Analysartikel • May 23
Omda AS (OB:OMDA) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected
Despite an already strong run, Omda AS ( OB:OMDA ) shares have been powering on, with a gain of 32% in the last thirty...Analysartikel • May 16
These 4 Measures Indicate That Omda (OB:OMDA) Is Using Debt Extensively
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Ny berättelse • May 08
Restructuring, Acquisitions And AI Integration Will Secure Operational Efficiency
Restructuring completion and an enhanced acquisition strategy are expected to boost operational efficiency, revenue growth, and earnings.Analysartikel • Apr 08
Little Excitement Around Omda AS' (OB:OMDA) Revenues
Omda AS' ( OB:OMDA ) price-to-sales (or "P/S") ratio of 1.7x might make it look like a buy right now compared to the...Analysartikel • Jan 26
Omda (OB:OMDA) Has A Somewhat Strained Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysartikel • Dec 21
The Market Doesn't Like What It Sees From Omda AS' (OB:OMDA) Revenues Yet
Omda AS' ( OB:OMDA ) price-to-sales (or "P/S") ratio of 1.5x might make it look like a buy right now compared to the...Analysartikel • Nov 13
Returns On Capital Are Showing Encouraging Signs At Omda (OB:OMDA)
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...Analysartikel • Jul 24
Returns At Omda (OB:OMDA) Are On The Way Up
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Typically, we'll want to notice a...Analysartikel • May 22
Omda's (OB:OMDA) Earnings Are Weaker Than They Seem
Despite posting some strong earnings, the market for Omda AS' ( OB:OMDA ) stock hasn't moved much. Our analysis...Analysartikel • Mar 24
Improved Revenues Required Before Omda AS (OB:OMDA) Stock's 28% Jump Looks Justified
Omda AS ( OB:OMDA ) shareholders are no doubt pleased to see that the share price has bounced 28% in the last month...Analysartikel • Jan 24
Fewer Investors Than Expected Jumping On Omda AS (OB:OMDA)
When close to half the companies operating in the Healthcare Services industry in Norway have price-to-sales ratios (or...Analysartikel • Nov 18
Omda's (OB:OMDA) Earnings May Just Be The Starting Point
Omda AS ( OB:OMDA ) recently posted some strong earnings, and the market responded positively. We have done some...Analysartikel • Jun 17
Are Investors Undervaluing CSAM Health Group AS (OB:CSAM) By 44%?
Key Insights The projected fair value for CSAM Health Group is kr81.03 based on 2 Stage Free Cash Flow to Equity CSAM...Aktieägarnas avkastning
| OMDA | NO Healthcare Services | NO Marknad | |
|---|---|---|---|
| 7D | 1.7% | 1.6% | 1.5% |
| 1Y | -27.8% | -23.1% | 15.1% |
Avkastning vs industri: OMDA presterade sämre än Norwegian Healthcare Services branschen som gav -23.1 % under det senaste året.
Avkastning vs Marknaden: OMDA presterade sämre än Norwegian marknaden som gav 15.1 % under det senaste året.
Prisvolatilitet
| OMDA volatility | |
|---|---|
| OMDA Average Weekly Movement | 5.7% |
| Healthcare Services Industry Average Movement | 5.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in NO Market | 10.6% |
| 10% least volatile stocks in NO Market | 2.9% |
Stabil aktiekurs: OMDA har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för Norwegian.
Volatilitet över tid: OMDA s veckovolatilitet ( 6% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1999 | 256 | Sverre Flatby | omda.com |
Omda AS tillhandahåller mjukvarulösningar för sjukvårdssektorn i Norge, Sverige, Danmark, Finland och internationellt. Företaget erbjuder system för hantering av laboratorieinformation, bestående av Omda ProSang, ett system för hantering av blod, celler och vävnader, samt lösningar för medicinering, bestående av Omda Cytodose, en lösning för hantering av onkologisk behandling. Bolaget tillhandahåller också lösningar för uppkopplad sjukvård, däribland Omda Cardio, ett verktyg för lagring av EKG och diagnostik; Omda CIMA, en mobilapp för medicinsk bildhantering; Omda Media, en webbaserad lösning för medicinsk bildhantering; Omda Medimaker, en lösning för bildhantering och arbetsflöde; Omda Picsara, en lösning för bildhantering; Omda Arcidis, ett integrerat teleradiologisystem; Omda Helsemail, ett verktyg för överföring av patientdata; Omda Plutus, en plattform för övervakning av revision och arbetsflöde; Omda S7, en plattform för säker kommunikation inom e-vård; och Omda XDS, en lösning för lagring och hantering av patientdata.
Omda AS Sammanfattning av grunderna
| OMDA grundläggande statistik | |
|---|---|
| Börsvärde | NOK 754.68m |
| Vinst(TTM) | -NOK 35.92m |
| Intäkter(TTM) | NOK 493.60m |
1.5x
P/S-förhållande-21.0x
P/E-förhållandeÄr OMDA övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| OMDA resultaträkning (TTM) | |
|---|---|
| Intäkter | NOK 493.60m |
| Kostnad för intäkter | NOK 258.75m |
| Bruttovinst | NOK 234.85m |
| Övriga kostnader | NOK 270.77m |
| Intäkter | -NOK 35.92m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
Aug 27, 2026
| Vinst per aktie (EPS) | -1.75 |
| Bruttomarginal | 47.58% |
| Nettovinstmarginal | -7.28% |
| Skuld/egenkapitalförhållande | -2,394.2% |
Hur har OMDA utvecklats på lång sikt?
Se historisk utveckling och jämförelseUtdelningar
1.3%
Aktuell utdelningsavkastning-27%
UtbetalningskvotFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/29 22:36 |
| Aktiekurs vid dagens slut | 2026/07/29 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Omda AS bevakas av 3 analytiker. 1 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Kristian Støle | Carnegie Investment Bank AB |
| Emilie Engen | DNB Carnegie |
| Eirik Rafdal | DNB Carnegie |